Organ transplant technology company hid that it forced product bundling on customers, (Jul 23, 2026)

TransMedics Group survived a motion to dismiss on securities fraud claims that it misrepresented forced bundling of its organ care system (OCS) with its National OCS Program (NOP) logistics service to hospitals. A Massachusetts federal court found plaintiffs adequately pleaded that the company's CEO made materially false statements denying forced bundling despite hospital witnesses testifying the practice was real.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.